Abstract
A patient with an FSH secreting pituitary adenoma is reported. Elevated FSH and serum free α-subunit (SU) with low levels of LH and testosterone (T) were found. Immunostaining showed the presence of α-SU, FSH-β and LH-β subunits. LHRH analogue (buserelin) was administered in a pulsatile manner, by portable computerized infusion pump sc for ten days. During the first 24 h of treatment FSH, LH (p < 0.001) and T (p < 0.01) rose significantly. Ten days later, the expected desensitization phenomenon did not occur, but further increases of T (8.4 ± 2.6, mean ± SD, vs 17.4 ± 4.1 nmol/l, p < 0.001) and FSH (58.9 ± 9.6 vs 70.7 ± 3.8 mlU/ml, p < 0.001) were registered. LH decreased (12.5 ± 2.4 vs 7.1 ± 0.6 mlU/ml, p < 0.001) at day 10, but remained higher than basal level (5.0 ± 0.6, p < 0.001). Free α-SU also rose (2.8 ± 0.4 vs 4.4 ± 1.7 mlU/ml, p < 0.001) after ten days of treatment. The chronic stimulatory effect of analogue on LH with a lack of desensitization suggests tumorous secretion despite a partially preserved negative feedback of testosterone. Low basal LH levels, in some patients with FSH secreting tumors may not be due to tumor mass effect, but rather may be the consequence of altered LH production and/or secretion by the tumor. Although bureselin may not have a therapeutic effect, it is of use in differential diagnosis of hypergonadotrophinemia.
Similar content being viewed by others
References
Kwekkeboom D.J., de Jong F.H., Lamberts S.W.J. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, and bromocriptine. J. Clin. Endocrinol. Metab. 68: 1128, 1989.
Roman S.H., Goldstein M., Kourides I.A., Comite F., Bardin W.C., Krieger D.T. The luteinizing hormone releasing hormone (LHRH) agonist (D-Trp6-Pro9-NEt) LHRH increased rather than lowered LH and α-subunit levels in a patient with LH-secreting pituitary tumor. J. Clin. Endocrinol. Metab. 58: 313, 1984.
Klinanski A., Deutch P., Jameson J.L., Ridgway E.C., Crowley W.C., Zervas N.T. Luteinizing hormone (LH) and α-subunit secreting adenoma: Biosyntetic characteriterization and clinical studies. J. Clin. Endocrinol. Metab. 64: 536, 1987.
Borges J.L.C., Ridgway E.C., Kovacs K., Rogol A.D., Thorner M.O. Follicle-stimulating hormone-secreting pituitary tumor with concomitant elevation of serum α-subunit levels. J. Clin. Endocrinol. Metab. 58: 937, 1984.
Friend J.N., Judge D.M., Sherman B.M., Santen R.J. FSH secreting pituitary adenomas: Stimulation and suppression studies in two patients. J. Clin. Endocinol. Metab. 43: 650, 1976.
Cunningham G.R., Huckins C. An FSH and prolactin-secreting pituitary tumor: Pituitary dynamics and testicular histology. J. Clin. Endocrinol. Metab. 44: 248, 1977.
Klibanski A., Shupnik M.A., Bikkal H.A., Black P. McL., Kliman B., Zervas N.T. Dopaminergic regulation of α-subunit secretion and messenger ribonucleic acid levels in α-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 65: 96, 1988.
Demura R., Kubo J.O., Odagiri E., Demura H., Kitamura K., Shizume K., The significance of α-subunit as a tumor marker for gonadotropin-producing pituitary adenomas. J. Clin. Endocrinol. Metab. 63: 564, 1986.
Snyder P.J., Sterling F.H. Hypersecretion of LH and FSH by a pituitary adenoma. J. Clin. Endocrinol. Metab. 42: 544, 1976.
Snyder P.P.J., Muzyka R., Johnson J., Utiger R.D. Thyrotropin-releasing hormone provokes abnormal follicle-stimulating hormone (FSH) and luteinizing hormone responses in men who have pituitary adenomas and FSH hypersecretion. J. Clin. Endocrinol. Metab. 51: 744, 1980.
Whitcomb R.W., Sangha J.S., Schneyer A.L., Crowley W.F. Jr. Improved measurement of free alpha subunit of glycoprotein hormones by assay with use of monoclonal antibody. Clin. Chem. 34: 2022, 1988.
Kourides I.O., Weintraub B.D., Rosen S.W., Ridgway E.C., Kliman B., Maloof F. Secretion of alpha subunit of glycoprotein hornones by pituitary adenomas. J. Clin. Endocrinol. Metab. 43: 97, 1976.
Peillon F., Bression B., Le Dafniet M., Brandi A.M., Li J.Y., Pagesy P., Birman P., Blumberg-Tick J., Michard M., Kujas M., Racadot J. Receptor studies in pituitary adenomas. Do they contribute to a better understanding of their pathogenesis? In: Landolt A.M., Heitz P.U., Zapf J., Girard J., Del Poso E. (Eds.), Advances in pituitary adenoma research. Pergamon Press, Oxford, 1988, p. 67.
Peterson R.E., Kourdies I.A., Horwith M., Darracot V. Jr, Saxena B.B., Fraser R.A.R. Luteinizing hormone- and α-subunit-secreting:pituitary tumor: Positive feedback of estrogen. J. Clin. Endocrinol. Metab. 52: 692, 1981.
Jameson L.L., Lindell C.M., Habener J.F. Gonadotropin and thyrotropin α- and β-subunit gene expression in normal and neplastic tissues characterised using specific messenger ribonucleic acid hybridization probes. J. Clin. Endocrinol. Metab. 64: 319, 1986.
Duet M., Warnet A., Roche D., Seret D., Diop S.N., Lubetzki J. Gonadotropic adenoma with abnormal secretory pattern: Case report adenoma. In: Landolt A.M., Heitz P.U., Zapf J., Girard J., Del Pozo E. (Eds.), Advances in pituitary adenoma research. Pergamon Press., Oxford, 1988, p. 433.
Yuan Q.X., Swerdloff R.S., Bhasin S. Differential regulation of rat luteinizing hormone α- and β-subunits during the stimulatory and down-regulatory phases of gonadotropin-releasing hormone action. Endocrinology. 122: 504, 1988.
Vogel D.L., Magner J.A., Sherins R.J., Weintraub B.D. Biosynthesis, glycosylation and secretion of rat luteinizing hormone α- and β-subunits: Differential effects of orchiectomy and gonadotropin-releasing hormone. Endocrinology 119: 202, 1986.
Gharib S.D., Bowers S.M., Need L.R., Chin W.W. Regulation of rat luteinizing hormone subunit messenger ribonucleic acids by gonadal steroid hormones. J. Clin. Invest. 77: 582, 1986.
Snyder P.J. Gonadotroph adenomas of the pituitary. J. Clin. Endocrinol. Metab. 6: 552, 1985.
Labrie F., Ferland L., Denizeau F., Beaulieu M. Sex steroids interact with dopamine at the hypothalamic and pituitary levels to modulate prolactin secretion. J. Steroid Biochem. 12: 323, 1980.
Berezin M., Olchovsky D., Pines A., Tadmor R., Lunenfeld B. Reduction of follicle-stimulating hormone (FSH) secretion in FSH producing pituitary adenoma by bromocriptine. J. Clin. Endocrinol. Metab. 59: 1220, 1984.
Vance M.L., Ridgway E.C., Thorner M.O. Follicle-stimulating hormone- and α-subunit-secreting pituitary tumor treated with bromocriptine. J. Clin. Endocrinol. Metab. 61: 580, 1985.
Sassolas G., Serusclat P., Claustrat B., Trouillas J., Merabet S., Cohen R., Souquet J.C. Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201–995). Horm. Res. 29: 124, 1988.
Vas P., Croughs R.J.M., Thijssen J.W., van’t Verlaat J.W., van Ginkel LA. Response of luteinizing hormone secreting pituitary adenoma to a long acting somatostatin analogue. Acta Endocrinol. (Copenh.) 118: 587, 1988.
Reubi J.C., Lamberts S.W.J., Maurer R. Somatostatin receptors in normal and tumoral tissue. Horm. Res. 29: 65, 1988.
Cook D.M., Watkins S., Snyder P.J. Gonadotrophin-secreting adenomas masquerading as primary ovarian failure. Clin. Endocrinol. (Oxf.) 25: 729, 1986.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Damjanović, S., Micić, D., Popović, V. et al. Follicle stimulating hormone - secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration. J Endocrinol Invest 14, 299–304 (1991). https://doi.org/10.1007/BF03346818
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346818